Trademarkia Logo

Canada

C$
PRECIGEN THERAPEUTICS
REGISTERED

on 16 Jul 2020

Last Applicant/ Owned by

PRECIGEN INC.

20358 Seneca Meadows PkwyGermantown, MD 20876

US

Serial Number

1856570 filed on 8th Sept 2017

Registration Number

TMA1080524 registered on 16th Jul 2020

Registration expiry Date

16th Jul 2030

Correspondent Address

OSLER, HOSKIN & HARCOURT LLP

SUITE 6200, P.O. BOX 501 FIRST CANADIAN PLACETORONTO

ONTARIO

CA

M5X1B8

PRECIGEN THERAPEUTICS

Trademark usage description

chemicals, biochemicals and reagents for use in industry and science, namely, scientific research purposes, laboratory use, manufacture of pharmaceuti Read More

Classification Information


Class [001]
Chemicals, biochemicals and reagents for use in industry and science, namely, scientific research purposes, laboratory use, manufacture of pharmaceuticals; chemicals, biochemicals and reagents, namely, proteins, nucleic acids, viral vectors and non-viral vectors for regulating, modifying or restricting gene expression.


Classification kind code

11

Class [005]
Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders.


Classification kind code

11

Class [042]
Scientific research and development services in the field of medicine, pharmacology, immunology, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare, namely, immunooncology, autoimmune disorders, infectious diseases, otology; Therapeutic research of treatment in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular disease; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use.


Classification kind code

11

Class [044]
Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, cardiovascular, immunological, and otological diseases and disorders; Medical services, namely, providing medical therapy treatments for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, otology, and cardiovascular diseases; Medical services, namely, genetic engineering, biopharmaceutical treatments and gene therapy services.


Classification kind code

11

Class [045]
Technology transfer services, namely, licensing of intellectual property


Classification kind code

11

Mark Details


Serial Number

1856570

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 42
on 8th Jan 2020
Advertised
Submitted for opposition 26
on 20th Dec 2019
Approved
Submitted for opposition 27
on 20th Dec 2019
Approval Notice Sent
Submitted for opposition 15
on 17th Oct 2019
Correspondence Created
Submitted for opposition 15
on 23rd Apr 2019
Correspondence Created
Submitted for opposition 22
on 20th Sept 2018
Search Recorded
Submitted for opposition 20
on 20th Sept 2018
Examiner's First Report
Submitted for opposition 31
on 13th Sept 2017
Formalized
Submitted for opposition 1
on 11th Sept 2017
Created
Submitted for opposition 30
on 8th Sept 2017
Filed